Events

DSECT/DSEN Monthly Seminar Series - Jan 27, 2017

DSECT AND CAN-AIM DSEN JOINT SEMINAR

——————————————————————————

“Using population-based data linkages and pan-Canadian networks to investigate multiple sclerosis (MS) drug safety and effectiveness”

Presented by

Prof. Helen Tremlett, PhD
Professor, Medicine (Neurology); Canada Research Chair in Multiple Sclerosis and Neuroepidemiology, University of British Columbia, Vancouver 

and

Dr. Kaarina Kowalec, PhD
Postdoctoral Researcher, Medicine (Neurology),
University of British Columbia, Vancouver

Thursday, January 26th at 3-4pm EST

Online via GoToWebinar

RSVP: https://attendee.gotowebinar.com/register/553163580539082241  

 

Download Event Flyer (PDF)

 

Abstract:

This presentation will discuss the use and linkage of population-based data to multiple sclerosis (MS) specialty clinic databases to answer questions regarding MS drug safety and effectiveness. We will also present methods on how to harness pan-Canadian and worldwide networks to identify pharmacogenomic biomarkers of serious adverse drug reactions to MS drugs, including a recent study on interferon-beta associated liver injury in MS.

Learning Objectives:

1. Gain insight into population-based data linkages and application to MS drug safety and effectiveness. 

Audience/chair to pick one of 2 questions:

  • What’s the cancer risk in MS and do the MS drugs (beta-interferon) alter cancer risk?
  • Do the disease modifying drugs impact long-term disease progression in clinical practice?

2. Harnessing pan-Canadian networks to identify pharmacogenomic biomarkers of beta-interferon associated liver injury in MS

Resources:

  • Website for the Canadian Network for Advanced Interdisciplinary Methods (CAN-AIM) for comparative effectiveness research: canaim.ca
  • Journal articles that may be discussed during the presentation:
    • Kingwell E, Bajdik C, Phillips N, Zhu F, Oger J, Hashimoto S, Tremlett H. Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain. 2012; 135:2973-2979

    • Kingwell E, Evans C, Zhu F, Oger J, Hashimoto S, Tremlett H. Assessment of cancer risk with beta-interferon treatment for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, Published 4 March 2014, doi:10.1136/jnnp-2013-307238

    • Shirani, A, Zhao Y, Karim M, Evans C, Kingwell E, van der Kop M, Oger J, Gustafson P, Petkau J, Tremlett H. Association between use of beta-interferon and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 Jul 18; 308(3):247-56

 

View Attached File